<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CARISOPRODOL- carisoprodol tablet </strong><br>A-S Medication Solutions LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use Carisoprodol Tablets, USP safely and effectively. See full prescribing information for Carisoprodol Tablets, USP.<br></span><span class="Bold"><br>Carisoprodol Tablets for Oral use CIV<br></span><span class="Bold"><br>Initial U.S. Approval: 1959</span>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Carisoprodol Tablets are indicated for the relief of <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> associated with acute, painful musculoskeletal conditions in adults. <a href="#LINK_5fb94131-fb61-450e-88f3-32ba77895f83">(1)</a> </p>
<p class="Highlighta">Limitations of Use:  </p>
<ul class="Disk"><li>Should only be used for acute treatment periods up to two or three weeks <a href="#LINK_5fb94131-fb61-450e-88f3-32ba77895f83">(1)</a>
</li></ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disk"><li>Recommended dose is 250 mg to 350 mg three times a day and at bedtime. <a href="#LINK_c2874dda-cedb-40b3-bd4a-0b61e47dec00">(2)</a>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 350 mg <a href="#LINK_8977788e-812a-4276-a654-14e6f9aaf1a1">(3)</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="4120604" conceptname="Acute intermittent porphyria">Acute intermittent porphyria</span> <a href="#LINK_d4474581-55a4-4501-9823-36890a4bb808">(4)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> to a carbamate such as meprobamate <a href="#LINK_d4474581-55a4-4501-9823-36890a4bb808">(4)</a>
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disk">
<li>Due to sedative properties, may impair ability to perform hazardous tasks such as driving or operating machinery <a href="#LINK_e0a46d9a-167b-4fd5-a9b2-61f354712751">(5.1)</a>
</li>
<li>Additive sedative effects when used with other CNS depressants including alcohol <a href="#LINK_e0a46d9a-167b-4fd5-a9b2-61f354712751">(5.1)</a>
</li>
<li>Cases of abuse, <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and withdrawal (<a href="#LINK_e0ebcabc-8416-43ed-91d3-1b469376de77">5.2</a>, <a href="#LINK_5a762142-8615-4a4e-b0ba-30c259518bb4">9.2</a>, <a href="#LINK_0e27a638-3035-4e04-a420-25db620630c1">9.3</a>) 
</li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> <a href="#LINK_d6aa6ab4-5596-401f-b09d-d083d56a913b">(5.3)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence &gt; 2%) are <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> <a href="#LINK_f1a6379b-c949-4f82-80c6-1e0e847e64eb">(6.1)</a> </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Qualitest Pharmaceuticals at 1‑800‑444-4011 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch</span>.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disk"><li>CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) - additive sedative effects (<a href="#LINK_e0a46d9a-167b-4fd5-a9b2-61f354712751">5.1</a>, <a href="#LINK_3728d51a-316e-4822-976e-a9e7ec79bca1">7.1</a>)</li></ul></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 2/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Sedation</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Abuse, <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span>, and Withdrawal</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 CNS Depressants</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 CYP2C19 Inhibitors and Inducers</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.8" class="toc">8.8 Patients with Reduced CYP2C19 Activity</a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-9.1" class="toc">9.1 Controlled Substance</a></h2>
<h2><a href="#section-9.2" class="toc">9.2 Abuse</a></h2>
<h2><a href="#section-9.3" class="toc">9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-12.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc"></a></h2>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 Sedation</a></h2>
<h2><a href="#section-16.2" class="toc">17.2 Avoidance of Alcohol and Other CNS Depressants</a></h2>
<h2><a href="#section-16.3" class="toc">17.3 Carisoprodol Tablets Should Only Be Used for Short-Term Treatment</a></h2>
<h2><a href="#section-16.4" class="toc"></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Carisoprodol Tablets are indicated for the relief of <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> associated with acute, painful musculoskeletal conditions in adults.</p>
<p>Carisoprodol Tablets should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration [<span class="Italics">see </span><span class="Italics"><a href="#LINK_c2874dda-cedb-40b3-bd4a-0b61e47dec00">Dosage and Administration (2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dose of carisoprodol is 250 mg to 350 mg three times a day and at bedtime. The recommended maximum duration of carisoprodol use is up to two or three weeks.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">350 mg Tablets: white, round, unscored tablets debossed "2410 V" on one side and plain on the reverse side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Carisoprodol Tablets are contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4120604" conceptname="Acute intermittent porphyria">acute intermittent porphyria</span> or a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to a carbamate such as meprobamate.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>5.1 Sedation</h2>
<p class="First">Carisoprodol has sedative properties (in the <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">low back pain</span> trials, 13% to 17% of patients who received carisoprodol experienced sedation compared to 6% of patients who received placebo) [<span class="Italics">see </span><span class="Italics"><a href="#LINK_f1a6379b-c949-4f82-80c6-1e0e847e64eb">ADVERSE REACTIONS (6.1)</a></span>] and may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a motor vehicle or operating machinery. There have been post-marketing reports of <span class="product-label-link" type="condition" conceptid="435134" conceptname="Motor vehicle accident">motor vehicle accidents</span> associated with the use of carisoprodol.</p>
<p>Since the sedative effects of carisoprodol and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive, appropriate caution should be exercised with patients who take more than one of these CNS depressants simultaneously.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2>5.2 Abuse, <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span>, and Withdrawal</h2>
<p class="First">Carisoprodol has been subject to abuse, <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, withdrawal, misuse, and criminal diversion. <span class="Italics">[see <a href="#LINK_737ea50e-61bf-496b-b013-d43d80c65ce0">Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> (9.1</a>, <a href="#LINK_5a762142-8615-4a4e-b0ba-30c259518bb4">9.2</a>, <a href="#LINK_0e27a638-3035-4e04-a420-25db620630c1">9.3)</a>]. </span>Abuse of carisoprodol poses a risk of overdosage which may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, CNS and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and other disorders <span class="Italics">[see <a href="#LINK_450ff6ad-b28c-4d87-8aec-fb29351274aa">Overdosage (10)</a>]. </span></p>
<p>Post-marketing experience cases of carisoprodol abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> have been reported in patients with prolonged use and a history of drug abuse. Although most of these patients took other drugs of abuse, some patients solely abused carisoprodol. Withdrawal symptoms have been reported following abrupt cessation of carisoprodol after prolonged use. Reported withdrawal symptoms included <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">muscle twitching</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, and <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. One of carisoprodol’s metabolites, meprobamate (a controlled substance), may also cause <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> <span class="Italics">[see <a href="#LINK_6b8dd546-401f-4aa5-bf82-19a5e38fb0ac">Clinical Pharmacology (12.3)</a>]. </span></p>
<p>To reduce the risk of carisoprodol abuse, assess the risk of abuse prior to prescribing. After prescribing, limit the length of treatment to three weeks for the relief of acute musculoskeletal <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, keep careful prescription records, monitor for signs of abuse and <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, and educate patients and their families about abuse and on proper storage and disposal.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></h2>
<p class="First">There have been postmarketing reports of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in patients who received carisoprodol. Most of these cases have occurred in the setting of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">multiple drug overdoses</span> (including drugs of abuse, illegal drugs, and alcohol) [<span class="Italics">see </span><span class="Italics"><a href="#LINK_450ff6ad-b28c-4d87-8aec-fb29351274aa">Overdosage (10)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience</h2>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect rates observed in practice.</p>
<p>The data described below are based on 1387 patients pooled from two double blind, randomized, multicenter, placebo controlled, one-week trials in adult patients with acute, mechanical, lower <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> [<span class="Italics">see <a href="#LINK_5b618ff1-4f96-475d-975e-5ef48685c087">Clinical Studies (14)</a></span>]. In these studies, patients were treated with 250 mg of carisoprodol, 350 mg of carisoprodol, or placebo three times a day and at bedtime for seven days. The mean age was about 41 years old with 54% females and 46% males and 74% Caucasian, 16% Black, 9% Asian, and 2% other.</p>
<p>There were no <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> and there were no serious adverse reactions in these two trials. In these two studies, 2.7%, 2%, and 5.4% of patients treated with placebo, 250 mg of carisoprodol, and 350 mg of carisoprodol, respectively, discontinued due to adverse events; and 0.5%, 0.5%, and 1.8% of patients treated with placebo, 250 mg of carisoprodol, and 350 mg of carisoprodol, respectively, discontinued due to central nervous system adverse reactions.</p>
<p>Table 1 displays adverse reactions reported with frequencies greater than 2% and more frequently than placebo in patients treated with carisoprodol in the two trials described above.</p>
<table>
<caption><span>Table 1. Patients with Adverse Reactions in Controlled Studies</span></caption>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="center"> <span class="Bold">Adverse<br>Reaction</span>
</td>
<td class="Botrule Lrule Rrule" align="center"> <span class="Bold">Placebo<br>(n=560)<br>n (%)</span>
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Carisoprodol 250 mg<br></span><span class="Bold">(n=548)<br></span><span class="Bold">n (%)</span> </p></td>
<td class="Botrule Lrule Rrule" align="center"> <span class="Bold">Carisoprodol 350 mg<br>(n=279)<br>n (%)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"> <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span></td>
<td class="Botrule Rrule" align="center"> 31 (6)</td>
<td class="Botrule Rrule" align="center"><p class="First">73 (13) </p></td>
<td class="Botrule Rrule" align="center"> 47 (17)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Rrule" align="center"> 11 (2)</td>
<td class="Botrule Rrule" align="center"> 43 (8)</td>
<td class="Botrule Rrule" align="center"> 19 (7)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Rrule" align="center"> 11 (2)</td>
<td class="Botrule Rrule" align="center"> 26 (5)</td>
<td class="Botrule Rrule" align="center"> 9 (3)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following events have been reported during postapproval use of carisoprodol. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Italics">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, and <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">facial flushing</span> [<span class="Italics">see </span><span class="Italics"><a href="#LINK_450ff6ad-b28c-4d87-8aec-fb29351274aa">Overdosage (10)</a></span>].</p>
<p><span class="Italics">Central Nervous System:</span> <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, depressive reactions, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> [<span class="Italics">see </span><span class="Italics"><a href="#LINK_450ff6ad-b28c-4d87-8aec-fb29351274aa">Overdosage (10)</a></span>].</p>
<p><span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">epigastric discomfort</span>.</p>
<p><span class="Italics">Hematologic: </span><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2>7.1 CNS Depressants</h2>
<p class="First">The sedative effects of carisoprodol and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive. Therefore, caution should be exercised with patients who take more than one of these CNS depressants simultaneously. Concomitant use of carisoprodol and meprobamate, a metabolite of carisoprodol, is not recommended [<span class="Italics">see </span><span class="Italics"><a href="#LINK_e0a46d9a-167b-4fd5-a9b2-61f354712751">Warnings and Precautions (5.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2>7.2 CYP2C19 Inhibitors and Inducers</h2>
<p class="First">Carisoprodol is metabolized in the liver by CYP2C19 to form meprobamate [<span class="Italics">see </span><span class="Italics"><a href="#LINK_6b8dd546-401f-4aa5-bf82-19a5e38fb0ac">Clinical Pharmacology (12.3)</a></span>]. Co-administration of CYP2C19 inhibitors, such as omeprazole or fluvoxamine, with carisoprodol could result in increased exposure of carisoprodol and decreased exposure of meprobamate. Co-administration of CYP2C19 inducers, such as rifampin or St. John's Wort, with carisoprodol could result in decreased exposure of carisoprodol and increased exposure of meprobamate. Low dose aspirin also showed an induction effect on CYP2C19. The full pharmacological impact of these potential alterations of exposures in terms of either efficacy or safety of carisoprodol is unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold">Pregnancy Category C.</span> There are no data on the use of carisoprodol during human pregnancy. Animal studies indicate that carisoprodol crosses the placenta and results in adverse effects on fetal growth and postnatal survival. The primary metabolite of carisoprodol, meprobamate, is an approved anxiolytic. Retrospective, post-marketing studies do not show a consistent association between maternal use of meprobamate and an increased risk for particular congenital malformations.</p>
<p><span class="Italics">Teratogenic effects: </span>Animal studies have not adequately evaluated the teratogenic effects of carisoprodol. There was no increase in the incidence of congenital malformations noted in reproductive studies in rats, rabbits, and mice treated with meprobamate. Retrospective, post-marketing studies of meprobamate during human pregnancy were equivocal for demonstrating an increased risk of congenital malformations following first trimester exposure. Across studies that indicated an increased risk, the types of malformations were inconsistent.</p>
<p><span class="Italics">Nonteratogenic effects:</span> In animal studies, carisoprodol reduced fetal weights, postnatal <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, and postnatal survival at maternal doses equivalent to 1 to 1.5 times the human dose (based on a body surface area comparison). Rats exposed to meprobamate <span class="Italics">in-utero</span> showed behavioral alterations that persisted into adulthood. For children exposed to meprobamate <span class="Italics">in-utero</span>, one study found no adverse effects on mental or motor development or IQ scores. Carisoprodol should be used during pregnancy only if the potential benefit justifies the risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">There is no information about the effects of carisoprodol on the mother and the fetus during labor and delivery.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Very limited data in humans show that carisoprodol is present in breast milk and may reach concentrations two to four times the maternal plasma concentrations. In one case report, a breast-fed infant received about 4 to 6% of the maternal daily dose through breast milk and experienced no adverse effects. However, milk production was inadequate and the baby was supplemented with formula. In lactation studies in mice, female pup survival and pup weight at weaning were decreased. This information suggests that maternal use of carisoprodol may lead to reduced or less effective infant feeding (due to sedation) and/or decreased milk production. Caution should be exercised when carisoprodol is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The efficacy, safety, and pharmacokinetics of carisoprodol in pediatric patients less than 16 years of age have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">The efficacy, safety, and pharmacokinetics of carisoprodol in patients over 65 years old have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The safety and pharmacokinetics of carisoprodol in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> have not been evaluated. Since carisoprodol is excreted by the kidney, caution should be exercised if carisoprodol is administered to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Carisoprodol is dialyzable by hemodialysis and peritoneal dialysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.7"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The safety and pharmacokinetics of carisoprodol in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> have not been evaluated. Since carisoprodol is metabolized in the liver, caution should be exercised if carisoprodol is administered to patients with impaired hepatic function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.8"></a><p></p>
<h2>8.8 Patients with Reduced CYP2C19 Activity</h2>
<p class="First">Patients with reduced CYP2C19 activity have higher exposure to carisoprodol. Therefore, caution should be exercised in administration of carisoprodol to these patients [<span class="Italics">see </span><span class="Italics"><a href="#LINK_6b8dd546-401f-4aa5-bf82-19a5e38fb0ac">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>9.1 Controlled Substance</h2>
<p class="First">Carisoprodol is a Schedule IV controlled substance. Carisoprodol has been subject to abuse, misuse, and criminal diversion for nontherapeutic use<span class="Italics"> [see <a href="#LINK_e0ebcabc-8416-43ed-91d3-1b469376de77">Warnings and Precautions (5.2)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>9.2 Abuse</h2>
<p class="First">Abuse of carisoprodol poses a risk of overdosage which may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, CNS and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and other disorders <span class="Italics">[see <a href="#LINK_e0ebcabc-8416-43ed-91d3-1b469376de77">Warnings and Precautions (5.2)</a> and <a href="#LINK_450ff6ad-b28c-4d87-8aec-fb29351274aa">Overdosage (10)</a>]</span>. Patients at high risk of carisoprodol abuse may include those with prolonged use of carisoprodol, with a history of drug abuse, or those who use carisoprodol in combination with other abused drugs.</p>
<p>Prescription drug abuse is the intentional non-therapeutic use of a drug, even once, for its rewarding psychological effects. <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug addiction</span>, which develops after repeated drug abuse, is characterized by a strong desire to take a drug despite harmful consequences, difficulty in controlling its use, giving a higher priority to drug use than to obligations, increased tolerance, and sometimes physical withdrawal. Drug abuse and <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug addiction</span> are separate and distinct from physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance (for example, abuse or addiction may not be accompanied by tolerance or physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>) <span class="Italics">[see <a href="#LINK_0e27a638-3035-4e04-a420-25db620630c1">Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> (9.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.3"></a><p></p>
<h2>9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">Tolerance is when a patient’s reaction to a specific dosage and concentration is progressively reduced in the absence of disease progression, requiring an increase in the dosage to maintain the same. Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> is characterized by withdrawal symptoms after abrupt discontinuation or a significant dose reduction of a drug. Both tolerance and physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> have been reported with the prolonged use of carisoprodol. Reported withdrawal symptoms with carisoprodol include <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">muscle twitching</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, and <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. Instruct patients taking large doses of carisoprodol or those taking the drug for a prolonged time to not abruptly stop carisoprodol <span class="Italics">[see <a href="#LINK_c1eedd0e-c843-4e57-8338-4bc8e88abb09">Warnings and Precautions (5.2)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Overdosage of carisoprodol commonly produces <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonic reactions</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">muscular incoordination</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, and/or <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> have been reported with carisoprodol overdosage. <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> has been reported with carisoprodol <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>. Many of the carisoprodol <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> have occurred in the setting of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">multiple drug overdoses</span> (including drugs of abuse, illegal drugs, and alcohol). The effects of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of carisoprodol and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) can be additive even when one of the drugs has been taken in the recommended dosage. Fatal accidental and non-accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of carisoprodol have been reported alone or in combination with CNS depressants.</p>
<p><span class="Bold">Treatment of Overdosage:</span> Basic life support measures should be instituted as dictated by the clinical presentation of the carisoprodol <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> should not be induced because of the risk of CNS and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, and subsequent <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span>. Circulatory support should be administered with volume infusion and vasopressor agents if needed. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> should be treated with intravenous benzodiazepines and the reoccurrence of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> may be treated with phenobarbital. In cases of severe <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, airway protective reflexes may be compromised and tracheal intubation should be considered for airway protection and respiratory support.</p>
<p>For decontamination in cases of severe toxicity, activated charcoal should be considered in a hospital setting in patients with large <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> who present early and are not demonstrating <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> and can protect their airway. </p>
<p>For more information on the management of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of carisoprodol, <span class="Bold">contact a Poison Control Center</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Carisoprodol Tablets, USP are available as 350 mg round, white tablets for oral administration. Carisoprodol is a white, crystalline powder, having a mild, characteristic odor and a bitter taste. It is slightly soluble in water; freely soluble in alcohol, in chloroform, and in acetone; and its solubility is practically independent of pH. Carisoprodol is present as a racemic mixture. Chemically, carisoprodol is N-isopropyl-2-methyl-2-propyl-1,3-propanediol dicarbamate and the molecular formula is C<span class="Sub">12</span>H<span class="Sub">24</span>N<span class="Sub">2</span>O<span class="Sub">4</span>, with a molecular weight of 260.33. The structural formula is:</p>
<div class="Figure"><img alt="This in an image of the structural formula of carisoprodol." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cfef5764-49ff-4ce2-84fe-5e421e4b0202&amp;name=carisoprodol-1.jpg"></div>
<p>Other ingredients in Carisoprodol Tablets, USP include croscarmellose sodium, hydrogenated vegetable oil, hypromellose, magnesium stearate and microcrystalline cellulose.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The mechanism of action of carisoprodol in relieving <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> associated with acute painful musculoskeletal conditions has not been clearly identified.</p>
<p>In animal studies, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">muscle relaxation</span> induced by carisoprodol is associated with altered interneuronal activity in the spinal cord and in the descending reticular formation of the brain.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-12.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Carisoprodol is a centrally acting skeletal muscle relaxant that does not directly relax skeletal muscles.</p>
<p>A metabolite of carisoprodol, meprobamate, has anxiolytic and sedative properties. The degree to which these properties of meprobamate contribute to the safety and efficacy of carisoprodol is unknown.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-12.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of carisoprodol and its metabolite meprobamate were studied in a crossover study of 24 healthy subjects (12 male and 12 female) who received single doses of 250 mg and 350 mg carisoprodol (see Table 2). The exposure of carisoprodol and meprobamate was dose proportional between the 250 mg and 350 mg doses. The C<span class="Sub">max</span> of meprobamate was 2.5 ± 0.5 μg/mL (mean ± SD) after administration of a single 350 mg dose of carisoprodol, which is approximately 30% of the C<span class="Sub">max</span> of meprobamate (approximately 8 μg/mL) after administration of a single 400 mg dose of meprobamate.</p>
<table>
<caption><span>Table 2. Pharmacokinetic Parameters of Carisoprodol and Meprobamate (Mean ± SD, n=24)</span></caption>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule" align="center"> </td>
<td class="Botrule Lrule" align="center"> <span class="Bold">250 mg  <br>Carisoprodol</span>
</td>
<td class="Botrule Lrule Rrule" align="center"> <span class="Bold">350 mg<br>Carisoprodol</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"> </td>
<td align="center"> <span class="Bold">Carisoprodol</span>
</td>
<td class="Botrule Rrule" align="center"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"> <span class="Bold">C<span class="Sub">max</span> (μg/mL)</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.2 ± 0.5</p></td>
<td class="Botrule Lrule Rrule" align="center"> 1.8 ± 1.0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"> <span class="Bold">AUC<span class="Sub">inf</span> (μg<span class="Sup">*</span>hr/mL)</span>
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4.5 ± 3.1</p></td>
<td class="Botrule Lrule Rrule" align="center"> 7.0 ± 5.0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"> <span class="Bold">T<span class="Sub">max</span> (hr)</span>
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.5 ± 0.8</p></td>
<td class="Botrule Lrule Rrule" align="center"> 1.7 ± 0.8</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"> <span class="Bold">T<span class="Sub">½</span> (hr)</span>
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.7 ± 0.5</p></td>
<td class="Botrule Lrule Rrule" align="center"> 2.0 ± 0.5</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"> </td>
<td align="center">
<span class="Bold">Meprobamate</span> </td>
<td class="Botrule Rrule" align="center"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"> <span class="Bold">C<span class="Sub">max</span> (μg/mL)</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.8 ± 0.3</p></td>
<td class="Botrule Lrule Rrule" align="center"> 2.5 ± 0.5</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"> <span class="Bold">AUC<span class="Sub">inf</span> (μg<span class="Sup">*</span>hr/mL)</span>
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">32 ± 6.2</p></td>
<td class="Botrule Lrule Rrule" align="center"> 46 ± 9.0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"> <span class="Bold">T<span class="Sub">max</span> (hr)</span>
</td>
<td class="Botrule Lrule Rrule" align="center"> 3.6 ± 1.7</td>
<td class="Botrule Lrule Rrule" align="center"> 4.5 ± 1.9</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"> <span class="Bold">T<span class="Sub">½</span> (hr)</span>
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9.7 ± 1.7 </p></td>
<td class="Botrule Lrule Rrule" align="center"> 9.6 ± 1.5</td>
</tr>
</tbody>
</table>
<p><span class="Italics">Absorption:</span> Absolute bioavailability of carisoprodol has not been determined. The mean time to peak plasma concentrations (T<span class="Sub">max</span>) of carisoprodol was approximately 1.5 to 2 hours. Co-administration of a high-fat meal with carisoprodol (350 mg tablet) had no effect on the pharmacokinetics of carisoprodol. Therefore, carisoprodol may be administered with or without food.</p>
<p><span class="Italics">Metabolism:</span> The major pathway of carisoprodol metabolism is via the liver by cytochrome enzyme CYP2C19 to form meprobamate. This enzyme exhibits genetic polymorphism (see Patients with Reduced CYP2C19 Activity below).</p>
<p><span class="Italics">Elimination:</span> Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours. The half-life of meprobamate is approximately 10 hours.</p>
<p><span class="Italics">Gender:</span> Exposure of carisoprodol is higher in female than in male subjects (approximately 30 to 50% on a weight adjusted basis). Overall exposure of meprobamate is comparable between female and male subjects.</p>
<p><span class="Italics">Patients with Reduced CYP2C19 Activity:</span> Carisoprodol should be used with caution in patients with reduced CYP2C19 activity. Published studies indicate that patients who are poor CYP2C19 metabolizers have a 4-fold increase in exposure to carisoprodol, and concomitant 50% reduced exposure to meprobamate compared to normal CYP2C19 metabolizers. The prevalence of poor metabolizers in Caucasians and African Americans is approximately 3 to 5% and in Asians is approximately 15 to 20%.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long term studies in animals have not been performed to evaluate the carcinogenic potential of carisoprodol.</p>
<p>Carisoprodol was not formally evaluated for genotoxicity. In published studies, carisoprodol was mutagenic in the <span class="Italics">in vitro </span>mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell assay in the absence of metabolizing enzymes, but was not mutagenic in the presence of metabolizing enzymes. Carisoprodol was clastogenic in the <span class="Italics">in vitro </span>chromosomal aberration assay using Chinese hamster ovary cells with or without the presence of metabolizing enzymes. Other types of genotoxic tests resulted in negative findings. Carisoprodol was not mutagenic in the Ames reverse mutation assay using <span class="Italics">S. typhimurium </span><span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> with or without metabolizing enzymes, and was not clastogenic in an <span class="Italics">in vivo </span>mouse micronucleus assay of circulating blood cells.</p>
<p>Carisoprodol was not formally evaluated for effects on fertility. Published reproductive studies of carisoprodol in mice found no alteration in fertility although an alteration in reproductive cycles characterized by a greater time spent in estrus was observed at a carisoprodol dose of 1200 mg/kg/day. In a 13-week toxicology study that did not determine fertility, mouse testes weight and sperm motility were reduced at a dose of 1200 mg/kg/day. In both studies, the no effect level was 750 mg/kg/day, corresponding to approximately 2.6 times the human equivalent dosage of 350 mg four times a day, based on a body surface area comparison. The significance of these findings for human fertility is not known.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The safety and efficacy of carisoprodol for the relief of acute, idiopathic mechanical <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">low back pain</span> was evaluated in two, 7-day, double blind, randomized, multicenter, placebo controlled, U.S. trials (Studies 1 and 2). Patients had to be 18 to 65 years old and had to have acute <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> (≤ 3 days of duration) to be included in the trials. Patients with chronic <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>; at increased risk for <span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">vertebral fracture</span> (e.g., history of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>); with a history of spinal pathology (e.g., herniated nucleus pulposis, <span class="product-label-link" type="condition" conceptid="4167097" conceptname="Spondylolisthesis">spondylolisthesis</span> or spinal stenosis); with inflammatory <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, or with evidence of a neurologic deficit were excluded from participation. Concomitant use of analgesics (e.g., acetaminophen, NSAIDs, tramadol, opioid agonists), other muscle relaxants, botulinum toxin, sedatives (e.g., barbiturates, benzodiazepines, promethazine hydrochloride), and anti-epileptic drugs was prohibited.</p>
<p>In Study 1, patients were randomized to one of three treatment groups (i.e., carisoprodol 250 mg, carisoprodol 350 mg, or placebo) and in Study 2 patients were randomized to two treatment groups (i.e., carisoprodol 250 mg or placebo). In both studies, patients received study medication three times a day and at bedtime for seven days.</p>
<p>The primary endpoints were the relief from starting <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">backache</span> and the global impression of change, as reported by patients, on Study Day 3. Both endpoints were scored on a 5-point rating scale from 0 (worst outcome) to 4 (best outcome) in both studies. The primary statistical comparison was between the carisoprodol 250 mg and placebo groups in both studies.</p>
<p>The proportion of patients who used concomitant acetaminophen, NSAIDs, tramadol, opioid agonists, other muscle relaxants, and benzodiazepines was similar in the treatment groups.</p>
<p>The results for the primary efficacy evaluations in the acute, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">low back pain</span> studies are presented in Table 3.</p>
<table>
<caption><span>Table 3. Results of the Primary Efficacy Endpoints<span class="Sup">a</span> in Studies 1 and 2</span></caption>
<col>
<col>
<col>
<col>
<col>
<tfoot>
<tr class="First">
<td class="Botrule Lrule" align="center"> </td>
<td class="Botrule Lrule" align="center"> </td>
<td class="Botrule Lrule" align="center"> </td>
<td class="Botrule Lrule" align="center"> </td>
<td class="Botrule Lrule Rrule" align="center"> </td>
</tr>
<tr>
<td class="Lrule" align="center"> </td>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Number of Patients</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="First">n=278 </p></td>
<td class="Botrule Lrule" align="center"> n=269</td>
<td class="Botrule Lrule Rrule" align="center"> </td>
</tr>
<tr>
<td class="Lrule" align="center"> </td>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Relief from Starting <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Backache</span>, Mean (SE)<span class="Sup">b</span></span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">1.1 (0.1) </p></td>
<td class="Botrule Lrule" align="center"><p class="First">1.8 (0.1) </p></td>
<td class="Botrule Lrule Rrule" align="center"> </td>
</tr>
<tr>
<td class="Lrule" align="center"><p class="First">  2 </p></td>
<td class="Botrule Lrule" align="center"><p class="First">Difference between Carisoprodol and Placebo, Mean (SE)<span class="Sup">b</span> (95% CI)</p></td>
<td class="Botrule Lrule" align="center"> </td>
<td class="Botrule Lrule" align="center"><p class="First">0.7 (0.5, 0.9)</p></td>
<td class="Botrule Lrule Rrule" align="center"> </td>
</tr>
<tr>
<td class="Lrule" align="center"> </td>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Global Impression of Change, Mean (SE)<span class="Sup">b</span></span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">1.7 (0.1) </p></td>
<td class="Botrule Lrule" align="center"><p class="First">2.2 (0.1) </p></td>
<td class="Botrule Lrule Rrule" align="center"> </td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"> </td>
<td class="Botrule Lrule" align="center"> Difference between Carisoprodol and Placebo, Mean (SE)<span class="Sup">b </span>(95% CI)</td>
<td class="Botrule Lrule" align="center"> </td>
<td class="Botrule Lrule" align="center"> 0.5 (0.4, 0.7)</td>
<td class="Botrule Lrule Rrule" align="center"> </td>
</tr>
<tr class="Last"><td></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule"> <span class="Bold">Study</span>
</td>
<td class="Botrule Lrule" align="center"> <span class="Bold">Parameter</span>
</td>
<td class="Botrule Lrule" align="center"> <span class="Bold">Placebo</span>
</td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Carisoprodol<br></span><span class="Bold">250 mg</span> </p></td>
<td class="Botrule Lrule Rrule" align="center"> <span class="Bold">Carisoprodol <br>350 mg</span>
</td>
</tr>
<tr>
<td class="Lrule" align="center"> </td>
<td class="Botrule Lrule Rrule"><span class="Bold">Number of Patients</span></td>
<td class="Botrule Lrule Rrule" align="center"> n=269</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">n=264 </p></td>
<td class="Botrule Lrule Rrule" align="center"> n=273</td>
</tr>
<tr>
<td class="Lrule" align="center"> </td>
<td class="Botrule Lrule Rrule"><span class="Bold">Relief from Starting <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Backache</span>, Mean (SE)<span class="Sup">b</span></span></td>
<td class="Botrule Lrule Rrule" align="center"> 1.4 (0.1)</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.8 (0.1) </p></td>
<td class="Botrule Lrule Rrule" align="center"> 1.8 (0.1)</td>
</tr>
<tr>
<td class="Lrule" align="center">  1</td>
<td class="Botrule Lrule Rrule" align="center">  Difference between Carisoprodol and Placebo, Mean (SE)<span class="Sup">b</span> (95% CI)</td>
<td class="Botrule Lrule Rrule" align="center"> </td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.4 (0.2, 0.5) </p></td>
<td class="Botrule Lrule Rrule" align="center"> 0.4 (0.2, 0.6)</td>
</tr>
<tr>
<td class="Lrule" align="center"> </td>
<td class="Botrule Lrule Rrule"><span class="Bold">Global Impression of Change, Mean (SE)<span class="Sup">b</span></span></td>
<td class="Botrule Lrule Rrule" align="center"> 1.9 (0.1)</td>
<td class="Botrule Lrule Rrule" align="center"> 2.2 (0.1)</td>
<td class="Botrule Lrule Rrule" align="center"> 2.2 (0.1)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center"> </td>
<td class="Botrule Lrule" align="center">  Difference between Carisoprodol and Placebo, Mean (SE)<span class="Sup">b</span> (95% CI)</td>
<td class="Botrule Lrule" align="center"> </td>
<td class="Botrule Lrule" align="center"><p class="First">0.2 (0.1, 0.4)</p></td>
<td class="Botrule Lrule Rrule" align="center"> 0.3 (0.1, 0.4)</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a </span>The primary efficacy endpoints (Relief from Starting <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Backache</span> and Global Impression of Change) were assessed by the patients on Study Day 3. These endpoints were scored on a 5-point rating scale from 0 (worst outcome) to 4 (best outcome). </p>
<p><span class="Sup">b</span> Mean is the least squared mean and SE is the standard error of the mean. The ANOVA model was used for the primary statistical comparison between the carisoprodol 250 mg and placebo groups.</p>
<p>Patients treated with carisoprodol experienced improvement in function as measured by the Roland-Morris <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">Disability</span> Questionnaire (RMDQ) score on Days 3 and 7.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">350 mg Tablets: white, round, unscored tablets debossed "2410 V" on one side and plain on the reverse side; available as follows:</p>
<ul class="Disk">
<li>Bottles of 100: NDC 0603-2582-21</li>
<li>Bottles of 500: NDC 0603-2582-28</li>
<li>Bottles of 1000: NDC 0603-2582-32</li>
</ul>
<div class="Section" data-sectionCode="44425-7">
<a name="section-15.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">Storage:</span><br>Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Patients should be advised to contact their physician if they experience any adverse reactions to carisoprodol tablets.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.1"></a><p></p>
<h2>17.1 Sedation</h2>
<p class="First">Patients should be advised that carisoprodol tablets may cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and/or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and has been associated with <span class="product-label-link" type="condition" conceptid="435134" conceptname="Motor vehicle accident">motor vehicle accidents</span>. Patients should be advised to avoid taking carisoprodol before engaging in potentially hazardous activities such as driving a motor vehicle or operating machinery [<span class="Italics">see <a href="#LINK_e0a46d9a-167b-4fd5-a9b2-61f354712751">Warnings and Precautions (5.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.2"></a><p></p>
<h2>17.2 Avoidance of Alcohol and Other CNS Depressants</h2>
<p class="First">Patients should be advised to avoid alcoholic beverages while taking carisoprodol tablets and to check with their doctor before taking other CNS depressants such as benzodiazepines, opioids, tricyclic antidepressants, sedating antihistamines, or other sedatives [<span class="Italics">see </span><span class="Italics"><a href="#LINK_e0a46d9a-167b-4fd5-a9b2-61f354712751">Warnings and Precautions (5.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.3"></a><p></p>
<h2>17.3 Carisoprodol Tablets Should Only Be Used for Short-Term Treatment</h2>
<p class="First">Patients should be advised that treatment with carisoprodol tablets should be limited to acute use (up to two or three weeks) for the relief of acute, musculoskeletal <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>. In the post-marketing experience with carisoprodol tablets, cases of <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, withdrawal, and abuse have been reported with prolonged use. If the musculoskeletal symptoms still persist, patients should contact their healthcare provider for further evaluation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.4"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Qualitest Pharmaceuticals at </span><span class="Bold">1-800-444-4011 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch.</span></span></p>
<p>Manufactured for:<br><span class="Bold">QUALITEST PHARMACEUTICALS</span><br>Huntsville, AL 35811</p>
<p>8181281<br>Revised: 2/2013<br>R7</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">NDC 54569-3403-1</span></p>
<p>Packaged by:<br><span class="Bold">A-S Medication Solutions</span><br>Libertyville, IL 60048</p>
<br><div class="Figure"><img alt="3403-1.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cfef5764-49ff-4ce2-84fe-5e421e4b0202&amp;name=3403-1.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CARISOPRODOL 		
					</strong><br><span class="contentTableReg">carisoprodol tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54569-3403(NDC:0603-2582)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CARISOPRODOL</strong> (CARISOPRODOL) </td>
<td class="formItem">CARISOPRODOL</td>
<td class="formItem">350 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">2410;V</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54569-3403-0</td>
<td class="formItem">28  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54569-3403-1</td>
<td class="formItem">7  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54569-3403-4</td>
<td class="formItem">12  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:54569-3403-5</td>
<td class="formItem">90  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:54569-3403-9</td>
<td class="formItem">45  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040245</td>
<td class="formItem">09/08/1997</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>A-S Medication Solutions LLC
							(830016429)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">A-S Medication Solutions LLC</td>
<td class="formItem"></td>
<td class="formItem">830016429</td>
<td class="formItem">repack(54569-3403)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0173aeef-5ee4-4ac8-ab97-ee8a085e20a5</div>
<div>Set id: cfef5764-49ff-4ce2-84fe-5e421e4b0202</div>
<div>Version: 1</div>
<div>Effective Time: 20130604</div>
</div>
</div> <div class="DistributorName">A-S Medication Solutions LLC</div></p>
</body></html>
